Cardiac Toxicity During Rituximab Administration

V GARYPIDOU Haematology Dept. of 2nd Prop Dept. of Internal Medicine, Aristotelian University of Thessaloniki, Ippokration General Hospital, Thessaloniki, GreeceCorrespondence[email protected]

V PERIFANIS Haematology Dept. of 2nd Prop Dept. of Internal Medicine, Aristotelian University of Thessaloniki, Ippokration General Hospital, Thessaloniki, Greece

K TZIOMALOS Haematology Dept. of 2nd Prop Dept. of Internal Medicine, Aristotelian University of Thessaloniki, Ippokration General Hospital, Thessaloniki, Greece

S THEODORIDOU Haematology Dept. of 2nd Prop Dept. of Internal Medicine, Aristotelian University of Thessaloniki, Ippokration General Hospital, Thessaloniki, Greece

References

Maloney, D.G. (2001) "Mechanism of action of rituximab", Antic-ancer Drugs, 12 (Suppl 2), SI —S4.
Google Scholar
Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", The New England Journal of Medicine, 346, 235 — 242.
Google Scholar
McLaughlin, P., Grillo-L6pez, A.J., Link, BK., Levy, R., Czuczman, M.S., Williams, M.E., et al. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825–2833.
PubMed Web of Science ®Google Scholar
Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., et al. (2001) "Rituximab therapy of patients with B-cell chronic lymphocytic leukemia", Blood, 98, 1326 — 1331.
Google Scholar
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. and Engert, A. (1999) "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)", Blood, 94, 2217 — 2224.
Google Scholar
van der Kolk, L.E., Grillo-Lopez, A.J., Baars, J.W., Hack, C.E. and van Oers, M.H.J. (2001) "Complement activation plays a key role in the side-effects of rituximab treatment", British Journal of Haema-tology, 115, 807–811.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cardiac Toxicity During Rituximab Administration

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cardiac Toxicity During Rituximab Administration

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date